MedTrace Logo

Argentinian Registry of Patients With Rheumatic Diseases and COVID-19 Infection

NCT04568421 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2982

Last updated 2023-02-01

No results posted yet for this study

Summary

SAR-COVID is a national, multicenter, prospective, observational longitudinal registry of consecutive patients with diagnosis of rheumatic diseases treated or not with immunomodulatory and/or immunosuppressive drugs and SARS-CoV-2 infection (asymptomatic or COVID-19).

Hypothesis: Patients with rheumatic diseases who are under chronic treatment with immunomodulatory and/or immunosuppressive drugs more frequently have an asymptomatic infection, a milder COVID-19 and lower mortality than patients with rheumatic diseases without immunomodulatory and/or immunosuppressive treatments.

Conditions

  • Rheumatic Diseases

Interventions

DRUG

Immunosuppressive Agents

Immunomodulatory and/or immunosuppressive drugs according to the indication of the treating physician

Sponsors & Collaborators

  • Sociedad Argentina de Reumatologia

    lead OTHER

Principal Investigators

  • Guillermo Pons-Estel · Unidad de Investigación Sociedad Argentina Reumatología

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-18
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04568421 on ClinicalTrials.gov